Revance Therapeutics Inc (RVNC)

[vinmantoo]

It certainly sounds as if unrealistic Daxxify expectations have been created. …. And at great harm to Revance’s share price potential.

It sure seems to be the case for the Daxxify launch. A big part of that appears to be the premium pricing strategy, which has been abandoned.

In another post on this thread, it seems that Daxx performance peaks long prior to six months after the tx. … and slowly deteriorates over the next three or four months during which the Patient cannot have another tx. (Daxxify or anything else?)

Every toxin used will hit a peak then start wearing off. That time happens earlier for Botox. Every toxin used has a time frame when you are not supposed to get another treatment. You seem to be suggesting it is only a problem for Daxxify. Is that true, and if so, why?

This may be why Abbvie is seeing a greater need for a shorter duration Botox than something which competes with the unrealistic daxxify expectations.

There could be market for short-term treatment but that is hardly a threat to Daxxify.

I doubt that the market is flat out wrong.

Markets are dramatically wrong all the time. I have made a lot of money because of that. Too soon to say whether that is the case for RVNC.